European medtech companies, especially ones in German-speaking nations, have a new well to draw from as Wellington Partners, the German venture capitalist, has closed its fifth fund at an over-subscribed €210m ($234m). Like its predecessor funds, Wellington Partners Life Science Fund V (WPLS-V) will primarily target European opportunities, although some allocations can be made in select North American and Asian businesses, across the medical life sciences spectrum including biopharma platforms, therapeutics, diagnostics, medical devices and digital health.
“We will continue to concentrate on investments in private companies from early-stage through to growth stage. We put emphasis on advanced phases of development, at a stage where the technological...